ClinicalTrials.gg

Program

Medroxyprogesterone Acetate

Also written as “Sayana Press”, “medroxyprogesterone acetate” and “TV-46046”.

Its studies are mostly in Neoplasms · Adenocarcinoma, led by 4 companies.

Furthest: phase 4, since Jan 24, 201711 company-led studies, 1 open or runningNext primary completion: Nov 4, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer50 open or runningphase 4since Jan 24, 2017May 10, 2007none ahead
Teva Pharmaceutical Industries40 open or runningphase 1since Jan 26, 2009Jan 26, 2009none ahead
Merck11 open or runningphase 2since May 13, 2025May 13, 2025Nov 4, 2027phase 2 · NCT06979596
Takeda10 open or runningphase 3since Nov 3, 2009Nov 3, 2009none ahead

Also a collaborator on its studies: mds-pharma-services.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 10, 2007First study: phase 1 study in PostmenopauseNew to PfizerPfizer · NCT00472927 · United States
  2. Oct 3, 2007Phase 1 study in PostmenopausePfizer · NCT00543634 · 30 enrolled · United States
  3. Feb 28, 2008Phase 1 study in MenopausePfizer · NCT00630435 · 76 enrolled
  4. Jan 26, 2009Teva Pharmaceutical Industries's first study: phase 1 study in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00830414 · 124 enrolled · Germany
  5. Nov 3, 2009Takeda's first study: phase 3 study in AdenocarcinomaNew to TakedaTakeda · NCT01011751 · 311 enrolled · France
  6. Jun 27, 2016Phase 1 study in PregnancyTeva Pharmaceutical Industries · NCT02817464 · 12 enrolled · United States
  7. Jan 24, 2017Phase 4 study in ContraceptionPfizer · NCT03034057 · 169 enrolled · United Kingdom
  8. Oct 3, 2018Phase 1 study in ContraceptionTeva Pharmaceutical Industries · NCT03700658 · 27 enrolled · Dominican Republic
  9. Dec 4, 2020Phase 1 study in ContraceptionTeva Pharmaceutical Industries · NCT04682353 · 60 enrolled · United States, Dominican Republic
  10. May 14, 2021Phase 1 study in HealthyPfizer · NCT04893798 · 67 enrolled · Belgium
  11. May 13, 2025Merck's first study: phase 2 study in NeoplasmsNew to MerckMerck · NCT06979596 · 250 planned · United States, Argentina, Brazil and more

Ahead

  1. Nov 4, 2027Primary completion: phase 2 study in NeoplasmsMerck · NCT06979596

TargetBeta

PGR →read by rule
“Progesterone receptor agonist”ChEMBL 37, by rule

Other programs on PGR

ProgramCompanyFurthest phaseStudies
LevonorgestrelruleBayerphase 456
drospirenoneruleestetraphase 420
Megestrol AcetateruleChangchun GeneScience Pharmaceuticalphase 419
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Utrogestanrulecalla-lily-clinical-care-ltdphase 11

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06979596Neoplasms · United States, Argentina, Brazil and more2RecruitingMerckNov 4, 2027250
NCT04893798Healthy · Belgium1CompletedPfizerJul 24, 202567
NCT04682353Contraception · United States, Dominican Republic1CompletedTeva Pharmaceutical IndustriesJul 11, 202260
NCT03700658Contraception · Dominican Republic1CompletedTeva Pharmaceutical IndustriesOct 2, 202027
NCT03034057Contraception · United Kingdom4CompletedPfizerDec 7, 2018169
NCT02817464Pregnancy · United States1CompletedTeva Pharmaceutical IndustriesDec 3, 201812
NCT01011751Adenocarcinoma · France3CompletedTakedaDec 2007311
NCT00830414Healthy · Germany1CompletedTeva Pharmaceutical IndustriesSep 2002124
NCT00630435Menopause1CompletedPfizerJun 200876
NCT00543634Postmenopause · United States1CompletedPfizerDec 200730
NCT00472927Postmenopause · United States1CompletedPfizer

How it is read

Names in the registry

  • “Sayana Press”, 2 entries
  • “medroxyprogesterone acetate”, 2 entries
  • “TV-46046”, 2 entries
  • “Premarin/MPA”, 2 entries
  • “Megestrol acetate/Medroxyprogesterone acetate”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.